Differential response of skeletal muscles to mTORC1 signaling during atrophy and hypertrophy by C Bentzinger et al.
Bentzinger et al. Skeletal Muscle 2013, 3:6
http://www.skeletalmusclejournal.com/content/3/1/6RESEARCH Open AccessDifferential response of skeletal muscles to
mTORC1 signaling during atrophy and
hypertrophy
C Florian Bentzinger1†, Shuo Lin1†, Klaas Romanino1, Perrine Castets1,2, Maitea Guridi1, Serge Summermatter1,
Christoph Handschin1, Lionel A Tintignac1,3, Michael N Hall1 and Markus A Rüegg1*Abstract
Background: Skeletal muscle mass is determined by the balance between protein synthesis and degradation.
Mammalian target of rapamycin complex 1 (mTORC1) is a master regulator of protein translation and has been
implicated in the control of muscle mass. Inactivation of mTORC1 by skeletal muscle-specific deletion of its
obligatory component raptor results in smaller muscles and a lethal dystrophy. Moreover, raptor-deficient muscles
are less oxidative through changes in the expression PGC-1α, a critical determinant of mitochondrial biogenesis.
These results suggest that activation of mTORC1 might be beneficial to skeletal muscle by providing resistance to
muscle atrophy and increasing oxidative function. Here, we tested this hypothesis by deletion of the mTORC1
inhibitor tuberous sclerosis complex (TSC) in muscle fibers.
Method: Skeletal muscles of mice with an acute or a permanent deletion of raptor or TSC1 were examined using
histological, biochemical and molecular biological methods. Response of the muscles to changes in mechanical
load and nerve input was investigated by ablation of synergistic muscles or by denervation .
Results: Genetic deletion or knockdown of raptor, causing inactivation of mTORC1, was sufficient to prevent
muscle growth and enhance muscle atrophy. Conversely, short-term activation of mTORC1 by knockdown of TSC
induced muscle fiber hypertrophy and atrophy-resistance upon denervation, in both fast tibialis anterior (TA) and
slow soleus muscles. Surprisingly, however, sustained activation of mTORC1 by genetic deletion of Tsc1 caused
muscle atrophy in all but soleus muscles. In contrast, oxidative capacity was increased in all muscles examined.
Consistently, TSC1-deficient soleus muscle was atrophy-resistant whereas TA underwent normal atrophy upon
denervation. Moreover, upon overloading, plantaris muscle did not display enhanced hypertrophy compared to
controls. Biochemical analysis indicated that the atrophy response of muscles was based on the suppressed
phosphorylation of PKB/Akt via feedback inhibition by mTORC1 and subsequent increased expression of the E3
ubiquitin ligases MuRF1 and atrogin-1/MAFbx. In contrast, expression of both E3 ligases was not increased in soleus
muscle suggesting the presence of compensatory mechanisms in this muscle.
Conclusions: Our study shows that the mTORC1- and the PKB/Akt-FoxO pathways are tightly interconnected and
differentially regulated depending on the muscle type. These results indicate that long-term activation of the
mTORC1 signaling axis is not a therapeutic option to promote muscle growth because of its strong feedback
induction of the E3 ubiquitin ligases involved in protein degradation.
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Skeletal muscle is the largest organ, accounting for 30 to
40% of the total body weight. Muscle tissue is highly
plastic and adapts its size to physical demand. For
example, increase in load causes hypertrophy whereas
unloading causes atrophy. Importantly, muscle atrophy
and subsequent wasting are also hallmarks of pathology
in muscular dystrophies or in cachexia, the latter being a
secondary consequence of a primary disease (for ex-
ample, AIDS, cancer or sepsis). Several lines of evidence
indicate that muscle mass is controlled by the balance
between protein synthesis and protein degradation [1,2].
In skeletal muscle, protein synthesis can be induced by
IGF1 (insulin-like growth factor-1), which in turn, acti-
vates PI3K (phosphatidylinositol 3-kinase) and PKB
(protein kinase B; also called Akt). Activated PKB/Akt
inhibits the protein complex TSC1-TSC2 (tuberous
sclerosis complex), which inactivates the small GTPase
protein Rheb (Ras homolog enriched in brain). Rheb
activates mammalian target of rapamycin complex 1
(mTORC1), which causes an increase in protein transla-
tion by phosphorylating its two best characterized tar-
gets S6K (p70S6 kinase) and 4EBP (eIF-4E-binding
protein). This IGF1-PI3K-PKB/Akt-mTOR signaling
pathway controls protein synthesis and cell size in sev-
eral tissues [3,4].
Activation of PKB/Akt also negatively regulates pro-
tein degradation by phosphorylating the FoxO (Forkhead
box O) transcription factors. Protein degradation is
mainly carried out by enzymes of the ubiquitin-
proteasomal and autophagosomal-lysosomal pathways
[5,6]. Dephosphorylated FoxOs in the nuclei promote
the expression of the two E3 ubiquitin ligases atrogin-1/
MAFbx and MuRF1 [7,8]. FoxOs have also been de-
scribed to drive expression of autophagy-related genes
[6,9]. The function of active PKB/Akt to simultaneously
stimulate protein synthesis and inhibit protein degra-
dation may explain the profound hypertrophic effect of
constitutively active PKB/Akt [10,11].
mTOR belongs to the PI3/PI4-kinase family; it is
highly conserved from yeast to human and assembles
into two structurally and functionally distinct multi-
protein complexes, called mTORC1 and mTORC2
[12,13]. An essential component of mTORC1 is the pro-
tein raptor (regulatory-associated protein of mTOR),
whereas rictor (rapamycin-insensitive companion of
mTOR) is an essential subunit of mTORC2 [3,4]. Most
functions of mTORC1 are acutely inhibited by the
immunosuppressant rapamycin, whereas mTORC2 is
only repressed by long-term application of rapamycin
[14]. In skeletal muscle, the function of mTORC2 seems
to not be essential because mice deficient for rictor have
no overt phenotype [15,16]. In contrast, mTORC1 par-
ticipates in the control of muscle size. For example,rapamycin prevents IGF1-induced growth of myotubes
[17], inhibits compensatory hypertrophy in rat skeletal
muscle [5] and blocks the growth-stimulating activity of
clenbuterol [18]. Moreover, transgenic overexpression of
TSC1 causes muscle atrophy in mice [19], while acute
overexpression of Rheb induces muscle hypertrophy
[20]. Finally, mice deficient for S6K1 show a reduction
of muscle fiber size and a blunted response to IGF1 [21].
In agreement with these findings, we recently showed
that mice with a skeletal muscle-specific knockout for
raptor (called RAmKO for raptor muscle knockout) have
a reduced muscle mass and suffer from a progressive
dystrophy, which causes their death at the age of four to
six months [16]. Muscles of RAmKO mice also have a
decreased oxidative capacity, which can be restored by
transgenic expression of PGC-1α [22]. In addition,
RAmKO mice show sustained activation of PKB/Akt
because of relieved feedback inhibition onto IRS1 (insulin
receptor substrate-1) by the diminished activation of
S6K [16].
Here we investigated the contribution of mTORC1 to
muscle atrophy and hypertrophy by targeting rptor (the
gene encoding raptor) or Tsc1 (encoding TSC1) specific-
ally in mouse skeletal muscle. We show that deletion of
rptor prevents muscle hypertrophy and enhances muscle
atrophy. Surprisingly, sustained activation of mTORC1
by the genetic deletion of Tsc1 does not induce hyper-
trophy but rather causes atrophy in all but soleus
muscles. While the TSC1-deficient, hypertrophic soleus
muscle is also resistant to denervation-induced atrophy,
tibialis anterior (TA) muscle atrophies like controls. Bio-
chemical characterization shows that regulation of the
two E3 ligases atrogin-1/MAFbx and MuRF1 differs
between TA and soleus muscles. Furthermore, we dem-
onstrate that all muscles show an increase in their oxida-
tive capacity upon mTORC1 activation. In summary, we
demonstrate that the oxidative capacity in all skeletal
muscles is controlled by mTORC1, whereas the effect of
sustained activation of mTORC1 on muscle size differs
between muscles. Hence, our studies decipher a mech-
anism of biological robustness that balances the two




Mice were maintained in a conventional facility with a
fixed dark–light cycle. Studies were carried out according
to criteria outlined for the care and use of laboratory ani-
mals and with approval of the Swiss authorities. RAmKO
mice were generated and genotyped as described before
[16]. Floxed Tsc1 mice [23] were obtained from The
Jackson Laboratory (Bar Harbor, Maine, USA) and mated
with mice expressing Cre recombinase under the human
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conditional Tsc1 allele was performed as described [23].
TSC-RAmKO mice were generated by intercrossing mice
carrying floxed rptor and Tsc1 alleles. Mice homozygous
for both floxed alleles were mated with double heterozy-
gotes, which also carried the HSA-Cre transgene. Except
for overloading experiments and Western blot analysis,
only male TSCmKO mice were used. Both genders were
used in RAmKO and TSC-RAmKO mice. All procedures
were performed in accordance with the Swiss regulations
for animal experimentation and they were approved by
the veterinary commission of the Canton Basel-Stadt.
Rapamycin treatment of mice
Rapamycin treatment began three days before the mice
were challenged with functional overload (FO) or elec-
troporation and continued until mice were sacrificed.
Rapamycin (LC Laboratories, Woburn, MA, USA), dis-
solved in saline containing 2% carboxymethylcellulose
(Sigma-Aldrich, St. Louis, MO, USA), was delivered
once daily by i.p. (intraperitoneal) injection at a dose of
1.5 mg/kg [5].
shRNA constructs
The methods to construct plasmids encoding shRNA
and the sequences of the Cd4 control shRNA and the
NLS-GFP construct have been described elsewhere [25].
The murine 19 nucleotide target sequences correspond to:
GTT GAT GCG TAA CCT TCT G (Tsc2), GAT GGA
CAC TGATGT TGT G (Tsc1) and GAATTT TGC TGA
TTT GGA A (rptor).
Tissue culture, transfections and shRNA efficiency
Adenoviruses encoding shRNA against Tsc2 and Cd4
were created by cloning the respective shRNA sequence
and H1 promoter from pSuper into pAd-DEST (Life
Technologies Europe B.V., Zug, Switzerland). To test the
efficiency of the Tsc2 shRNA, C2C12 myoblasts, cultured
under standard conditions, were transfected with the
Tsc2 and Cd4 shRNA viruses. The efficiency of the rptor
shRNA was tested by co-transfection with an expression
plasmid encoding HA-tagged raptor into COS7 cells using
Lipofectamine 2000 (Life Technologies). For PGC1β
overexpression and knockdown, myoblasts were permitted
to fuse into multinucleated myotubes for 48 hr and cells
were infected with adenovirus preparations for an add-
itional 48 hr. Adenoviruses (Ad-GFP, Ad-PGC1β, Ad-
scrambled or Ad-siPGC1β) were kindly provided by BM
Spiegelman (Harvard University, Boston, MA, USA).
Electroporation of muscle
Plasmids encoding shRNA constructs were electroporated
into muscle fibers as described before [25]. Briefly, soleus
or TA muscle of anesthetized mice was exposed andinjected with 10 to 30 μl of a mixture containing the
respective shRNA plasmid and a plasmid coding for
NLS-GFP (2 mg/ml of each construct). The fascia and
the skin were sutured and the electroporation was
performed using an ECM 830 electroporation system
(BTX Instruments Division, Harvard Apparatus Inc.,
Holliston, MA, USA). Eight pulses lasting 20 ms with
the frequency of 1 Hz and the voltage set to 180 V/
cm were applied. Mice were analyzed four to six
weeks after electroporation.Denervation, nerve crush and overloading
Mice were anesthetized with ketamine (111 mg/kg) and
xylazine (22 mg/kg) by intra-peritoneal injection and sur-
gery was performed under aseptic conditions. For denerv-
ation, a segment (approximately 5 mm) of the sciatic
nerve at the mid-thigh level was excised [26]. To induce
muscle re-growth, the nerve was crushed with No 5
Dupont forceps (Fine Science Tools GmbH, Heidelberg,
Germany) for 10 seconds at mid-thigh [27]. To induce
muscle hypertrophy, a functional overload of plantaris
muscle was introduced by surgical removal of soleus and
gastrocnemius muscles [28]. Surgery was performed on
one leg only. The plantaris muscle of the contralateral leg
served as control.Antibodies
The antibodies used were from the following sources:
rabbit polyclonal antibodies directed to 4E-BP1 (Phas-I)
from Zymed (Life Technologies); those recognizing
Phospho-4E-BP1 (Ser65), PKB/Akt, mTOR, S6 Riboso-
mal Protein or Phospho-S6 Ribosomal Protein (Ser235/
236) were all from Cell Signaling Technology Inc. (Dan-
vers, MA, USA); those against FoxO1a were from
Abcam plc. (Cambridge, UK); those against TSC1 were
from Bethyl Laboratories (Montgomery, TX, USA).
Rabbit monoclonal antibodies directed against Phospho-
Akt (Ser473), IRS-1, FoxO3a (75D8) and phospho-
FoxO1(Thr24)/FoxO3a(Thr32) (#9466) were from Cell
Signaling Technology Inc. Mouse monoclonal antibodies
to α-actinin were purchased from Sigma and antibodies
against HA from Covance Inc. (Geneva, Switzerland).
Rat monoclonal antibodies directed to the Laminin B2
Chain (MAB1914) were from Chemicon and sold by
Millipore AG (Zug, Switzerland). The TSC2 antibodies
used were described elsewhere [29]. Mouse monoclonal
antibodies against myosin heavy chain: slow (A4.840),
IIa/IIx (A4.74) and IIb (BF-F3) were purchased from
The Developmental Studies Hybridoma Bank (University
of Iowa, Iowa City, Iowa, USA). Antibodies to puro-
mycin [30] were a kind gift of Dr. Philippe Pierre (CIML
Parc Scientifique de Luminy, Marseille, France).
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Muscles frozen in liquid nitrogen-cooled isopentane
were cut into 12 μm cross-sections. Cross-sections were
fixed with 2% paraformaldehyde (PFA) and perme-
abilized with 1% Triton/PBS for 5 minutes, washed with
100 mM glycine/PBS for 15 minutes, blocked with 1%
BSA/PBS for 30 minutes, and incubated with the pri-
mary antibody overnight at 4°C. Samples were subse-
quently washed three times for 10 minutes each with 1%
BSA/PBS and stained with the appropriate fluorescence la-
beled secondary antibodies for 1 hr at room temperature.
After washing with PBS, samples were mounted with
Citifluor (Citifluor Ltd. London, UK). General histology
on cross-sections was performed using hematoxylin
and eosin (H&E; Merck, Zug, Switzerland). NADH-TR
(Nicotinamide adenine dinucleotide hydrogen-tetrazolium
reductase) staining was done as described [31]. Methods
of SDH and COX staining were described elsewhere [22].
Samples were dehydrated and mounted with DePeX
mounting medium (Gurr, BDH, VWR International
GmbH, Dietikon, Switzerland).In vivo protein synthesis
Protein synthesis was measured using the surface sens-
ing of translation (SUnSET) method [30] by i.p. injection
of 0.040 μmol/g puromycin dissolved in 100 μl of PBS.
Mice were sacrificed 30 minutes later and muscles were
snap-frozen in liquid nitrogen. Muscles were lysed as
described below and proteins were separated on 8 to
16% SDS-PAGE (Bio-Rad Laboratories AG, Cressier,
Switzerland). After transfer to polyvinyl difluoride mem-
branes and blocking of free binding sites with 5% milk
powder in Tris-buffered saline with 0.1% Tween 20
(TBST), the mouse IgG2a monoclonal anti-puromycin
antibody (clone 12D10; 1:5,000) was incubated for 1 hr
at room temperature. After incubation with the appropri-
ate HRP-coupled secondary antibody, blots were de-
veloped using enhanced chemiluminescence reagent.
Coomassie Blue staining was used to verify equal loading.Tissue homogenization, SDS-PAGE and Western blot
Muscles frozen in liquid nitrogen were powdered on dry
ice and lysed in cold RIPA buffer supplemented with 1%
Triton-X, 10% glycerol, protease inhibitor cocktail tab-
lets (Roche Diagnostics AG, Rotkreuz, Switzerland), and
phosphatase inhibitor cocktail I and II (Sigma). Cell
lysates were incubated on ice for 2 hr, sonicated two
times for 15 s and centrifuged at 13,600 g for 30 minutes
at 4°C. Cleared lysates were then used to determine total
protein levels (BCA Protein Assay, Pierce, Rockford, IL,
USA). After dilution with sample buffer, equal protein
amounts were loaded onto SDS gels.Real-time PCR
Total RNA was isolated (SV Total RNA Isolation Sys-
tem, Promega AG, Dübendorf, Switzerland) from soleus
muscles. RNA concentrations were adjusted between
samples and reverse transcription was carried out using
a mixture of oligodT and random hexamer primers
(iScript cDNA Synthesis Kit, Bio-Rad Laboratories AG).
Sybr Green, real-time PCR analysis (Power SYBR Green
Master Mix, Life Technologies) was performed using the
ABI Prism 7000 Sequence Detector. Expression levels
for each gene of interest were normalized to the expres-
sion of the housekeeping protein β-actin. The following
primers were used: β-actin sense primer: 5' CAG CTT
CTT TGC AGC TCC TT, antisense primer: 5' GCA GCG
ATA TCG TCA TCC A; atrogin-1/MAFbx sense primer:
5' CTC TGT ACC ATG CCG TTC CT, antisense primer:
5' GGC TGC TGA ACA GAT TCT CC; MuRF-1 sense
primer: 50 ACC TGC TGG TGG AAA ACATC, antisense
primer: 50 AGG AGC AAG TAG GCA CCT CA; Pgc1α
sense primer: 5’ TGA TGT GAA TGA CTT GGA TAC
AGA CA, antisense primer: 5’ GCT CAT TGT TGT ACT
GGT TGG ATA TG; Pgc1β sense primer: 5' GGC AGG
TTC AAC CCC GA, antisense primer: 5' CTT GCT AAC
ATC ACA GAG GAT ATC TTG. Quantification of mito-
chondrial DNA copy numbers was done as described [22].
Quantifications and statistics
For muscle fiber size quantification, muscle cross-
sections were stained either for laminin-γ1 or fluores-
cence labeled wheat-germ agglutinin. Images were
acquired using a Leica DM5000B fluorescence micro-
scope with 10x objective, a digital camera (F-View; Soft
Imaging System, Olympus Soft Imaging Solutions
GmbH, Münster, Germany), and analySIS software (Soft
Imaging System). Images of the entire soleus or tibialis
anterior (TA) muscles were aligned with Adobe Pho-
toShop (Adobe Systems Incorporated, San Jose, CA,
USA). The minimum distance of parallel tangents at op-
posing particle borders (minimal feret’s diameter) and
cross-section area (CSA) were measured with analySIS
software as described [32]. Data are expressed as mean ±
SEM. For statistical comparison of two conditions, the
Student’s t- test was used. The level of significance is
indicated as follows: *** P <0.001, ** P <0.01, * P <0.05.
Results
Acute changes in mTORC1 activity affect muscle fiber size
To evaluate the potential of mTORC1 in regulating
muscle fiber size, we first tested the effect of mTORC1
inhibition or activation in normal weight-bearing mus-
cles and in acute models of muscle hypertrophy and
atrophy. To this end, we electroporated plasmids encod-
ing an shRNA directed against rptor (to inactivate
mTORC1) or Tsc2 (to activate mTORC1) into muscle
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described [25]. As a negative control, shRNA constructs
directed against Cd4 were used. To label targeted muscle
fibers, a plasmid coding for nuclear-localized GFP (NLS-
GFP) was co-electroporated with all shRNA constructs.
Before electroporation into muscle, each shRNA construct
was tested in tissue culture using either COS cells co-
transfected with the corresponding expression plasmidFigure 1 Acute perturbation of mTORC1 affects muscle fiber size. Sole
to transcripts encoding CD4 (Cd4), raptor (Rptor) or TSC2 (Tsc2). Plasmids en
After four to six weeks, muscle fiber size was determined by staining mid-b
Transfected muscle fibers were identified by the expression of nuclear-loca
were innervated muscle (A, B), reinnervated muscle after nerve crush (C, D
sectional area (CSA) of muscle fibers in each paradigm are given relative to
Electroporation of plasmids encoding shRNA to Cd4 served as control. Scal
mice and N ≥200 fibers were measured in each). In case of innervated mu
denervated muscles electroporated with shRNA to Cd4, data represent mea
otherwise indicated, significance was determined compared to the control(Additional file 1: Figure S1A) or by infecting myoblasts
with adenovirus expressing the corresponding shRNA
construct (Additional file 1: Figure S1B). Four to six weeks
after electroporation, transfected muscle fibers were iden-
tified by their expression of NLS-GFP in myonuclei
(Figure 1) and the size of GFP-positive fibers was com-
pared with that of neighboring, non-transfected fibers.
Knockdown of raptor resulted in a small but significantus muscle was electroporated with plasmids encoding shRNA directed
coding NLS-GFP were co-electroporated to label transfected fibers.
elly cross-sections with Alexa-594-labeled wheat germ agglutinin (red).
lized GFP (green; white asterisks). The experimental paradigms used
) and denervated muscle (E, F). Quantifications (B, D, F) of cross-
CSA of neighboring, GFP-negative, non-electroporated fibers.
e bars (A, C, E) = 50 μm. Bars (B, D, F) represent mean ± SEM (N ≥3
scles treated with shRNA to Tsc2 and with rapamycin (Tsc2 + Rapa) and
n ± SD (N = 2). P-values are ***P <0.001; **P <0.01; *P <0.05. Unless
(shRNA to Cd4).
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TSC2 resulted in a significant increase (Figure 1A, B).
Consistent with the notion that TSC1/2 acts via mTORC1,
rapamycin fully prevented the muscle hypertrophy ob-
served in TSC2 knockdown fibers (Figure 1A, B). As
expected, electroporation of shRNA constructs targeting
Tsc1 resulted in a hypertrophy response very similar to the
Tsc2 knockdown (Additional file 1: Figure S1C, D).
To test the role of mTORC1 in muscle plasticity, we
crushed the sciatic nerve unilaterally immediately after
electroporation, which causes a transient denervation-Figure 2 Conditional inactivation of TSC1 in skeletal muscle. (A) Weste
TSCmKO mice using antibodies directed against the proteins indicated. α-a
gastrocnemius (GC), plantaris (PL), tibialis anterior (TA), extensor digitorum lon
(ctrl) mice. Weight is expressed as a percentage of the weight of the same m
(N = 8 to 12 mice for each genotype). Data are mean ± SEM; ***P <0.001; **P
TA and soleus muscles of control and TSCmKO mice. Scale bar = 50 μm. (D, E
TSCmKO and control mice (N = 4). More details of fiber size analysis are showinduced atrophy, followed by fiber re-innervation and
re-growth to normal size [27,33,34]. Such “hypertrophy
on recovery” (HOR) was significantly less in muscle fi-
bers expressing shRNA to rptor and significantly higher
in fibers expressing shRNA to Tsc2 (Figure 1C, D). To
test whether shRNA-targeting acted on the initial atro-
phy or on re-growth, we also examined electroporated
muscle fibers in a pure denervation-induced atrophy
paradigm. No difference between non-electroporated
and electroporated fibers was detected in Cd4 controls
(Figure 1E, F). In contrast, muscle fibers expressingrn blot analysis of soleus muscle from 90-day-old control (ctrl) and
ctinin is used as a loading control. (B) Weight of soleus (Sol),
gus (EDL) and triceps (Tri) muscles of TSCmKO and littermate control
uscle in control mice after normalization to the total body weight
<0.01; *P <0.05; Student’s t-test. (C) H&E staining of cross-sections from
) Fiber size distribution in soleus (D) and TA (E) muscles of 90-day-old
n in Additional file 1: Figure S3 and in Additional file 1, Table S1. *P <0.05.
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fibers and, like in innervated muscle, the effect of TSC2
knockdown was abrogated by rapamycin (Figure 1E, F).
Similar results were obtained by electroporating tibialis
anterior (TA) muscle (Additional file 1, Figure S1E, F).
These results thus show that acute alteration of mTORC1
activity affects the response of both, the slow oxidative
soleus and fast glycolytic TA muscles to growth-stimulating
and atrophy-inducing conditions.
Constitutive deletion of Tsc1 in skeletal muscle fibers
affects muscles differentially
To examine whether sustained activation of mTORC1
would lead to the same effects observed in our electro-
poration paradigm, mice carrying floxed alleles for Tsc1
[23] were crossed with mice that express Cre recombin-
ase under the control of the muscle fiber-specific human
skeletal actin (HSA) promoter [24]. Mice lacking TSC1
in skeletal muscle (herein called TSCmKO, for TSC
muscle knockout) were born at the expected Mendelian
ratio and, at birth, could not be visually distinguished
from their littermate controls. Muscle extracts from
TSCmKO mice were largely devoid of TSC1 (Figure 2A).
Moreover, they showed the expected increase inTable 1 Quantification of Western blot analysis
TSCmKO
p-mTORS2448 19 ± 2***
mTOR 31 ± 6
P-4E-BP1S65 23 ± 5***
4E-BP1 34 ± 6
P-S6S235/S236 53 ± 1***
S6 48 ± 11
IRS-1 6 ± 2***
P-PKB/ AktS473 4 ± 2***
PKB/ Akt 28 ± 7
FoxO1 23 ± 5
FoxO3a 16 ± 7
P-FoxO1T24/3aT23 2 ± 7**/ 8 ± 3* 11
P-PKB/ AktS473 (Den. TA) n.d.
P-S6S235/S236 (Den. TA) 47 ± 12***
P-PKB/ AktS473 (Den. Sol) n.d.
P-S6S235/S236 (Den. Sol) 41 ± 10**
RAmKO
P-PKB/ AktS473 (Den. TA) 12 ± 2
P-S6S235/S236 (Den. TA) n.d.
P-PKB/ AktS473 (Den. Sol) 19 ± 3
P-S6S235/S236 (Den. Sol) n.d.
Proteins were extracted from soleus (Sol) and tibialis anterior (TA) muscles of 90-day
“n.d” denotes: not detectable. The amount of total protein loaded onto the SDS-PA
levels. Numbers given represent average gray values ± SEM after subtraction of the
knockout animal divided by the gray values from the control littermates. “Number
number of Ctrl littermates was always the same or higher than the values given. P-phosphorylation of mTOR at the mTORC1-selective site
Serine 2448 and of the mTORC1 targets S6 and 4EBP
(Figure 2A; Table 1 for quantification). These data are
similar to those obtained in other tissues where Tsc1 or
Tsc2 were conditionally ablated [23,35-37].
Consistent with the activation of the mTORC1 targets
and the role of mTORC1 in the control of protein trans-
lation, protein synthesis in EDL muscle of TSCmKO was
increased (Additional file 1: Figure S2A). However,
TSCmKO mice gained less weight than their control lit-
termates. Starting from the age of five weeks, male
TSCmKO mice were significantly lighter (Additional file 1:
Figure S2B), whereas the weight difference in females did
not reach significance (Additional file 1: Figure S2C). At
least part of this weight difference was due to alteration in
muscle mass as all but soleus muscles were significantly
lighter than in control mice (Figure 2B). Thus, despite
increased protein synthesis, all but soleus muscles are
lighter in TSCmKO mice than in control mice.
To investigate the reason for these muscle-specific dif-
ferences in weight, we focused on soleus and TA muscles
in three-month-old mice. Hematoxylin & eosin (H&E)
staining did not reveal any major alterations in either of
the muscles (Figure 2C). The difference in the muscleCtrl Ratio Number of replicates
10 ± 1 1.9 4
28 ± 5 1.1 4
12 ± 3 1.9 4
39 ± 6 0.9 4
13 ± 6 4 4
42 ± 17 1.1 4
24 ± 1 0.3 4
22 ± 3 0.2 4
22 ± 6 1.2 4
18 ± 3 1.3 4
17 ± 5 0.9 4
± 2/ 20 ± 5 0.2/ 0.4 4
n.d. n.d. 3
5 ± 2 9.4 3
n.d. n.d. 3
3 ± 5 13.7 3
Ctrl ratio number of replicates
2 ± 1 6 3
n.d. n.d. 3
3 ± 2 6.3 3
n.d. n.d. 3
-old TSCmKO, RAmKO or control (Ctrl) littermates. “Den.” denotes: denervated.
GE was adjusted and Western blots were additionally normalized to α-actinin
background. “Ratio” represents the average gray value obtained from a
of replicates” represents the number of knockout animals analyzed. The
values were determined by Student’s t-test; * P <0.05, ** P <0.01, ***P <0.001.
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in soleus and TA muscle (Figure 2D, E). Detailed analysis
of fiber types showed that both type I and type IIa fibers
were larger in soleus muscle (Additional file 1: Figure S3;
Additional file 1: Table S1). In TA muscle, the glycolytic
type IIb fibers were significantly smaller whereas the oxi-
dative type IIa/x fibers were not affected (Additional file 1:
Figure S3, Additional file 1: Table S1). In summary, these
data show that the response to the activation of mTORC1
differs between muscles and fiber types.
We have previously shown that deletion of rptor not
only affects the immediate downstream targets of
mTORC1, S6K and 4EBP, but also causes a strong increaseFigure 3 mTORC1 activation affects the PKB/Akt and PGC1 pathways.
(ctrl) and TSCmKO mice using antibodies directed against the proteins indi
expression of atrogin-1/MAFbx (Atr-1) and MuRF1 in TA and soleus muscles
expression of β-actin and control muscles were set to 100% (TA: N ≥4 mice
is shown in TA (D) and soleus (E) muscles of TSCmKO and control mice. All
muscles from control littermates were set to 100%. TA: N ≥4; Sol: N ≥5. No
mice. (F) Relative mRNA levels of Pgc1α in differentiated C2C12 cells that w
(ad-GFP), PGC1β (ad-PGC1β), shRNA to a scrambled sequence (ad-siScr) or
(ad-GFP and ad-siScr) and were set to 100% (N = 9). Note that expression o
represent mean ± SEM. P-values are ***P <0.001; **P <0.01; *P <0.05; Stude
-old control and TSCmKO mice. Both muscles of TSCmKO are more oxidatiin the phosphorylation of PKB/Akt [16]. As shown in
Figure 3A, IRS1 levels were low in soleus muscle of
TSCmKO mice compared to control (Figure 3A; Table 1).
In addition, phosphorylation of PKB/Akt and of FoxO1/3
was substantially decreased in TSCmKO mice compared
to controls (Figure 3A; Table 1). The same alterations in
expression levels and phosphorylation of the examined
proteins were detected in TA muscle of TSCmKO mice
(data not shown). Consistent with the low phosphoryl-
ation levels of FoxO1a and FoxO3a, transcript levels of
atrogin-1/MAFbx or MuRF-1 were much higher in TA
muscle of TSCmKO than in control mice (Figure 3B). Sur-
prisingly, in soleus muscle, transcript levels of atrogin-1/(A) Western blot analysis of soleus muscles from 90-day-old control
cated. α-actinin is used as loading control. (B, C) Relative mRNA
of TSCmKO and control mice. All values were normalized to the
; Sol: N ≥5 mice). (D, E) Relative mRNA expression of Pgc1α and Pgc1β
values are normalized to expression of β-actin. Relative expression in
te that levels of Pgc1β but not Pgc1α are up-regulated in TSCmKO
ere infected with adenoviral vectors encoding GFP
shRNA to Pgc1β (ad-siPGC1β). Values are normalized to each control
f Pgc1α inversely correlates with PGC1β levels. Quantitative data (B-F)
nt’s t-test. (G) NADH-TR staining of TA and soleus muscles of 90-day
ve. Scale bar = 50 μm.
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despite the low levels of phosphorylation of PKB/Akt.
These data argue that the differential expression of the two
E3 ligases might be responsible for the selective hyper-
trophy in soleusmuscle.
Sustained activation of mTORC1 increases the oxidative
capacity in all muscles
Additional factors that are regulated by mTORC1
[16,22,38] and have been implicated in the control of
muscle size are the transcriptional coactivators PGC1α
and PGC1β [39,40]. Moreover, PGC1α and PGC1β are
major regulators of mitochondrial biogenesis [41]. To
test whether deletion of Tsc1 would also affect the PGC1
pathway and the oxidative capacity of skeletal muscle,
we next compared expression of Pgc1α and Pgc1β in TA
and soleus muscles of TSCmKO mice with littermate
controls. Contrary to the expectation, transcript levels of
Pgc1α were decreased in mutant muscles compared to
controls (Figure 3D, E). The down-regulation of Pgc1α
was more pronounced in soleus muscle, which expresses
the highest level of PGC1α in wild-type mice [42]. In
contrast, mRNA levels of Pgc1β were increased to about
150% in all examined muscles of TSCmKO mice
(Figure 3D, E). In support of a direct regulation of Pgc1β
transcripts by mTORC1, Pgc1β expression was dimin-
ished in RAmKO mice (soleus muscle in RAmKO mice:
73 ± 4.6%; control mice: 100 ± 10.3%; mean ± SEM;
N ≥5; P <0.05). Hence, unlike expression of the E3 ubi-
quitin ligases atrogin-1/MAFbx and MuRF1, expression
of Pgc1α and Pgc1β did not differ between TA and soleus
muscles in TSCmKO mice. Overexpression and knock-
down experiments of PGC1β in C2C12 myotubes indi-
cate that expression of Pgc1α is tightly regulated by
PGC1β (Figure 3F). Such counter-regulation between
PGC1α and PGC1β has also been reported in other tis-
sues [43]. Thus, the increased levels of Pgc1β transcripts
in the TSCmKO mice likely suppress expression of
Pgc1α. Interestingly, TSCmKO mice showed an increase
in their capacity for oxidative phosphorylation in TA
and soleus muscles as shown by stainings for NADH-TR
(Figure 3G), succinate dehydrogenase (SDH; Additional
file 1: Figure S4A, B) and cytochrome oxidase (COX;
Additional file 1: Figure S4A, B). This increase was ac-
companied by a slight, although not significant, increase
in the number of mitochondria as determined by qPCR
of mitochondrial DNA (Additional file 1: Figure S4C).
Taken together, these data suggest that PGC1β is re-
sponsible for the increased oxidative properties of skel-
etal muscle of TSCmKO mice.
mTORC1 is required for muscle fiber hypertrophy
Because acute perturbation of mTORC1 function by
knockdown experiments showed a strong effect on musclesize in experimental paradigms of HOR and denervation-
induced atrophy (Figure 1), we next tested muscle plasti-
city in RAmKO and TSCmKO mice. We first used the
synergist ablation/mechanical overload model, in which
gastrocnemius and soleus muscles including their tendons
are surgically removed, a procedure that results in the
functional overloading (FO) of the remaining plantaris
muscle [44-46]. Seven or 28 days after surgery, mice were
euthanized and the plantaris muscle of the overloaded leg
was compared with plantaris from the contralateral,
sham-operated leg. In control mice, FO increased muscle
weight after 7 days to 140% and to more than 200% after
28 days (Figure 4A). Muscle weight also increased in
RAmKO mice, although the increase was significantly re-
duced compared to control animals after 28 days of FO
(Figure 4A). However, and in contrast to control mice
(Figures 4B and S5A), individual muscle fibers did not in-
crease in size in RAmKO mice after 7 days (Additional file
1: Figure S5B) or after 28 days of FO (Figure 4C). H&E
staining of the plantaris after 28 days of FO did not reveal
differences between contralateral and overloaded RAmKO
muscles (Figure 4D). In contrast to RAmKO mice,
TSCmKO muscle responded to FO like control muscle
(Figure 4E-G).
There is evidence that FO also causes some damage and
muscle regeneration and that satellite and other cells out-
side the muscle’s basal lamina contribute to the weight
increase [47,48]. As HSA-Cre is not expressed in non-
muscle cells and satellite cells [24], we treated control
mice with rapamycin during FO to eliminate mTORC1
function in all cells. This treatment abolished both the
increase in weight and the shift in fiber size distribution
(Additional file 1: Figure S5C), suggesting that mTORC1
expressed in non-muscle cells or in satellite cells might
contribute to the increased weight of plantaris muscles in
RAmKO mice after FO.
As FO induces a relative increase in the number of oxi-
dative fibers [46], we also stained the overloaded plantaris
from control and mutant mice by NADH-TR. As shown
in Figure 4H, plantaris muscles remained largely non-
oxidative in RAmKO mice, whereas in the overloaded
plantaris of TSCmKO mice even the large myofibers
remained highly oxidative (Figure 4I).
Soleus and TA muscles of TSCmKO mice respond
differently to denervation-induced atrophy
To determine whether mTORC1 activation is sufficient to
prevent atrophy, we next submitted TSCmKO muscle to
denervation by cutting the sciatic nerve unilaterally and
compared the muscles of the denervated and the contra-
lateral (non-denervated) leg six days later. TA and soleus
muscles of control mice lost 7% and 14% of their weight,
respectively (Figure 5A). Importantly, the weight loss in
both muscles was significantly higher in RAmKO mice
Figure 4 Growth of muscle upon functional overloading. (A) Plantaris muscles of control (ctrl) and RAmKO mice were functionally overloaded
(FO) by ablation of the soleus and gastrocnemius muscles. Muscle weight of plantaris was measured after 7 or 28 days of FO and is expressed as
the percentage of the weight of the contralateral, non-overloaded muscle (7 days FO: N ≥5 mice; 28 days FO: N ≥7 mice). (B, C) Fiber size
distribution of the contralateral (dashed line) and FO (closed line) plantaris muscle of control (B) and RAmKO (C) mice after 28 days of FO (N = 7).
(D) H&E staining of overloaded and contralateral plantaris muscles after FO for 28 days in control and RAmKO mice. (E) Muscle weight after 28
days of FO in control and TSCmKO mice (N = 5). (F) Fiber size distribution of non-overloaded, contralateral (dashed line) and over-loaded plantaris
muscles (solid line) after 28 days of FO in TSCmKO mice (N = 5). (G) H&E staining of overloaded and contralateral plantaris muscles after 28 days of FO
from TSCmKO mice. (H, I) NADH-TR staining of plantaris muscles after 28 days FO in mice with the indicated genotype. Scale bars (D, G, H, I) = 50 μm.
Individual data points and bars of quantitative data represent mean ± SEM. P-values are ***P <0.001; **P <0.01; *P <0.05; Student’s t-test.
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vation differed between TA and soleus muscles. Whereas
loss of weight in the TA was the same in TSCmKO and
control mice, soleus muscles of TSCmKO mice were
largely spared (Figure 5A). H&E staining of the denervated
muscles and contralateral muscles did not reveal major
structural changes in mutant mice (Figure 5B, C). In soleus
muscles, the substantial weight loss upon denervation in
control and RAmKO mice was mirrored by a shift in fiber
size distribution. The leftward shift was seen in control
mice (Figure 5D) and was even more pronounced in
RAmKO mice (Figure 5E). In TSCmKO mice, muscle
fiber size distribution also shifted slightly toward smaller
size when compared to the hypertrophic, contralateral in-
nervated soleus muscles (Figure 5F), but remained similarto innervated muscle from control mice. These results
suggest that TA and soleus muscles differ in the response
to mTORC1 activation under atrophy conditions and they
suggest that the atrophy observed in the TSCmKO mice
requires adaptive, long-term processes that are not
induced by acute perturbation of mTORC1 signaling (see
Figure 1). In both TSCmKO and control mice, the TA
muscle showed a loss of oxidative capacity upon dener-
vation (Figure 5G) whereas the soleus muscle of TSCmKO
mice remained oxidative (Figure 5H).
Feedback control of PKB/Akt is active during muscle
atrophy
The difference in the atrophy response between TA and
soleus muscles indicated that the underlying signaling
Figure 5 Muscle atrophy induced by denervation. (A) Loss (Δ) of muscle weight in tibialis anterior (TA) and soleus (Sol) muscles after six days
of denervation using mice of the indicated genotype. Data are expressed as percentage of weight loss compared to the non-denervated contralateral
muscle in the same mouse. N ≥4 mice for RAmKO and control littermates (ctrl); N ≥5 mice for TSCmKO and control littermates. (B, C) H&E staining of
soleus muscle after six days of denervation in mice of the indicated genotype. (D-F) Fiber size distribution in soleus muscle after six days of denervation
(solid line) and in the contralateral, non-denervated muscle (dashed line) of mice with the indicated genotype. Note that the most frequent fiber size in
the denervated TSCmKO muscle is the same as that of innervated control muscle (blue arrowheads). N ≥4 for RAmKO and control littermates; N = 5 for
TSCmKO and control littermates. (G, H) NADH-TR staining of TA and soleus muscles after six days of denervation in control and TSCmKO mice. Scale bars
(B, C, G, H) = 50 μm. Quantification represent mean ± SEM. P-values are ***P <0.001; **P <0.01; *P <0.05 using the Student’s t-test.
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examine this, we analyzed the changes in expression of
the E3 ligases atrogin-1/MAFbx and MURF1, and the
coactivators Pgc1α and Pgc1β in response to denervation.
Denervation has been reported to activate mTORC1,
most likely due to the increase in free amino acids [49].
However, in RAmKO mice phosphorylation of S6K, S6
and 4EBP remained low six days after denervation
(Table 1 and data not shown) whereas phosphorylation
at Serine 473 of PKB/Akt remained high in RAmKO
mice (Figure 6A). In parallel to the activation state of
PKB/Akt, denervation increased transcript levels of
atrogin-1/MAFbx and MuRF-1 in TA and soleus muscles
of control mice but not of RAmKO mice (Figure 6B, C).The effect on the expression of the two E3 ubiquitin
ligases was particularly striking in soleus muscles where
their expression did not differ from innervated control
muscles (Figure 6C). In TSCmKO mice, phosphorylated
PKB/Akt was too low to be detected in denervated mus-
cles (Table 1) but phosphorylation of S6 remained high
(Figure 6D). Although phosphorylation of PKB/Akt was
low in both TA and soleus muscles, transcript levels of
atrogin-1/MAFbx and MuRF-1 were increased in TA but
were significantly lower in soleus compared to the dener-
vated muscles from control mice (Figure 6E, F, Table 1).
The expression of the mTORC1 target PGC1α is also
controlled by denervation [39]. In innervated soleus
muscle of RAmKO mice, Pgc1α mRNA levels are less
Figure 6 Changes in mTORC1-dependent signaling in denervated muscles. (A, D) Western blot analysis of tibialis anterior (TA) and soleus (Sol)
muscles after six days of denervation using antibodies against PKB/Akt phosphorylated at Serine 473 (A) and S6 phosphorylated at Serines 235/236 (D). α-
actinin was used as a loading control. (B, C, E, F) Relative mRNA levels of atrogin-1/MAFbx (Atr-1) and MuRF1 as determined by qPCR in TA and soleus (Sol)
muscles after six days of denervation. Note that expression of both E3 ligases is blunted in RAmKO mice (B, C), while this response is exaggerated in TA (E)
but not in soleus muscles (F) of TSCmKO mice. (G – J) Relative mRNA levels of Pgc1α and Pgc1β in RAmKO (G, H) and TSCmKO (I, J) mice after six days of
denervation. All values are normalized to the expression levels of the transcript measured in innervated muscle of control littermates (set to 100%). N ≥4
mice for TA and N ≥5 mice for soleus of each genotype. Values represent mean ± SEM. P-values are ***P <0.001; **P <0.01; *P <0.05; Student’s t-test.
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mately 70% of control muscle. In denervated TA and so-
leus muscles of control mice, expression of Pgc1α and
Pgc1β was lower than in innervated muscle (Figure 6G, H).
Similarly, denervation lowered the levels of both transcrip-
tional co-activators in RAmKO mice although the signifi-
cant difference to control mice was lost (Figure 6G, H).
In contrast, expression of Pgc1α and Pgc1β was very
different in TSCmKO mice. While Pgc1α mRNA levels
were decreased upon denervation both in TA and soleus
muscles, Pgc1β was significantly increased in both
muscles (Figure 6I, J). Taken together, our results show
that atrophy is accelerated in RAmKO mice despite low
levels of atrogin-1/MAFbx and MuRF1. Conversely, the
sparing of soleus muscles from denervation-induced
atrophy in TSCmKO mice could be based on the lowlevels of the two E3 ubiquitin ligases in this particular
muscle. In contrast, the relative levels of Pgc1α and
Pgc1β did not differ between TA and soleus muscles
upon denervation and are thus unlikely contributors to
the differential response.
Genetic inactivation of mTORC1 reverses the phenotype
of TSCmKO mice
While the inhibitory function of TSC1/2 onto mTORC1
is well established, there is evidence that this protein
complex can also regulate mTORC2 [50,51]. To test
whether any of the effects observed in TSCmKO mice
would be maintained in RAmKO mice, we generated
double knockout mice (termed TSC-RAmKO). First, we
examined phosphorylation of known mTORC1 and
mTORC2 substrates. As shown in Figure 7A, the
Figure 7 TSC1-raptor double knockouts resemble RAmKO mice. (A) Western blot analysis of soleus muscles of TSCmKO, TSC-RAmKO and control
(ctrl) mice using antibodies directed against the proteins indicated. An equal amount of protein was loaded in each lane. Loading control was α-actinin.
(B) Muscle weight of the tibialis anterior (TA) and soleus (Sol) muscles of TSC-RAmKO and control mice. Muscle weight was first normalized to the body
weight and is expressed as percentage of the weight of the same muscle from control mice (N = 3 mice for each genotype). (C) Relative mRNA
expression of Pgc1α and Pgc1β in soleus muscle of TSC-RAmKO and ctrl mice. Values obtained in control mice were set to 100% (N = 3 mice). Bars in B and
C represent mean ± SEM. P-values are ***P <0.001; **P <0.01; *P <0.05. (D) NADH-TR staining of soleus muscle from TSC-RAmKO and control mice. Scale
bar = 100 μm. (E) Schematic drawing of the major signaling pathways regulated by mTORC1 and their influence on protein synthesis and degradation.
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lated in TSC-RAmKO mice and phosphorylation of
PKB/Akt at Serine 473 was increased compared to con-
trol mice. In addition, similar to RAmKO mice, the PKB/
Akt target FoxO3a was hyperphosphorylated. The weight
of all muscles including TA and soleus was lower in TSC-
RAmKO mice than in controls (Figure 7B). Moreover,
transcript levels of both Pgc1α and Pgc1β were lower in
soleus muscle (Figure 7C) and its oxidative capacity was
decreased (Figure 7D). Finally, the TSC-RAmKO mice de-
veloped the same pathology as the RAmKO mice and they
eventually died at the age of four to six months (data not
shown). Thus, all the hallmarks of RAmKO mice are
present in the double mutants, indicating that TSC acts
mainly via mTORC1 in skeletal muscle.
Discussion
Here we describe the phenotype of mice in which
mTORC1 is constitutively active in skeletal muscle
(TSCmKO) and compare it to mice with inactivated
mTORC1 signaling (RAmKO). While the oxidative
changes in TSCmKO mice were largely the opposite ofthose observed in RAmKO mice and affected all examined
muscles, the effect of mTORC1 activation on muscle size
was unexpected as all muscles except soleus muscles were
slightly but significantly smaller. Thus, our work highlights
the existence of several feed-forward or auto-inhibitory
loops that allow fine-tuning of the signaling networks in-
volved in the control of muscle mass (Figure 7E).
Based on the current concepts, mTORC1 activation
should result in an increase in muscle mass and muscle
fiber size. This view is based on the findings that activa-
tion of the mTORC1 upstream components PKB/Akt or
IGF-1 receptor causes an increase in muscle mass
[5,10,11,52,53] and that this increase is rapamycin-
sensitive [11,53]. Moreover, overexpression of Rheb in
single muscle fibers by electroporation leads to hyper-
trophy of the transfected fibers [20] and whole body
knockout of the mTORC1 target S6K1 results in smaller
muscle fibers [21]. Consistent with these experiments,
acute knockdown of TSC1/2 by shRNA resulted in
slightly bigger muscle fibers in soleus or TA muscles,
confirming that transient activation of the mTORC1
pathway is sufficient to induce muscle fiber growth.
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mTORC1 in TSCmKO mice, all muscles examined, with
the exception of soleus, were smaller than in control
mice. As mTORC1 targets are activated and protein syn-
thesis in EDL muscle of TSCmKO mice is increased, the
atrophy induced by chronic mTORC1 activation is likely
related to the feedback inhibition of activated S6K onto
IRS1, which in turn, decreases activation of PKB/Akt.
This tight feedback control of S6K on IRS1-PKB/Akt
was also observed in mice deficient for raptor or mTOR
in some tissues including skeletal and heart muscle
[16,54-56] but not in others [57]. Similarly, deletion of
TSC1 strongly decreases activation of PKB/Akt in cul-
tured mouse embryonic fibroblasts [23], whereas it does
not at all affect PKB/Akt phosphorylation in some tis-
sues [58,59]. These data indicate that the feedback con-
trol of S6K depends on the cellular context and our data
now show that this feedback is particularly strong in
skeletal muscle.
Consistent with decreased inhibition of FoxO tran-
scription factors by PKB/Akt, TA muscle from TSCmKO
mice express high levels of MuRF1 and atrogin-1/
MAFbx, involved in protein degradation through the
proteasome [7,8]. Hence, the atrophy observed in mus-
cles of the TSCmKO mice is likely caused by the preva-
lence of the FoxO pathway over mTORC1 activation.
This differs from the muscle hypertrophy observed using
the transient, partial activation of mTORC1 with shRNA
electroporation. Thus, the atrophy response caused by
the sustained, saturated mTORC1 activation by genetic
Tsc1 deletion may unveil a long-term adaptation of the
FoxO pathway. Consistently, transient overexpression of
Rheb does not seem to affect PKB/Akt phosphorylation
[20], further supporting the idea that muscle atrophy in
TSCmKO mice is related to the indirect PKB/Akt-
dependent activation of FoxO pathways.
Importantly, contrasting with the atrophic phenotype of
most muscles, sustained activation of mTORC1 leads to
increased mass of soleus muscle in TSCmKO mice. Al-
though PKB/Akt was similarly inhibited in soleus and TA
muscles, expression of MuRF1 and atrogin-1/MAFbx was
not increased in soleus muscle, indicating that an add-
itional regulatory mechanism suppresses their expression,
thereby overruling the regulation by PKB/Akt. This differ-
ential regulation of MuRF1 and atrogin-1/MAFbx expres-
sion did not seem to be mediated by PGC1α, previously
identified as a negative regulator of FoxO [39], because
there was no significant difference in PGC1α/β expression
between soleus and TA muscles from TSCmKO mice.
With different atrophy and hypertrophy paradigms, we
also demonstrate that mTORC1 plays a critical and
complex role in muscle plasticity. Using shRNA electro-
poration, we show that transient activation of mTORC1
is sufficient to limit denervation-induced atrophy and toenhance fiber hypertrophy upon re-innervation. Simi-
larly, TSCmKO mice display atrophy resistance to de-
nervation in soleus muscle, which shows only moderate
expression of the E3 ubiquitin ligases MuRF1 and
atrogin-1/MAFbx. By contrast, long-term activation of
mTORC1 did not protect TA muscle from atrophy and
did not exacerbate the hypertrophy response to
overloading of plantaris muscle. These results indicate
that the increased protein synthesis by mTORC1
hyperactivation is not sufficient to maintain muscle mass
in cases where the FoxO-MuRF1-atrogin-1/MAFbx axis
is active due to the absence of PKB/Akt signaling. Im-
portantly, both transient and long-term inactivation of
mTORC1 increased denervation-induced atrophy and
prevented muscle growth associated with re-innervation
or overloading, indicating that increased protein synthe-
sis is required even when the catabolic proteasomal ac-
tivity is reduced. Thus, our results provide genetic
evidence that muscle growth requires mTORC1.
In our previous work, we demonstrated that raptor-
deficient skeletal muscles show a strongly decreased oxi-
dative capacity due to changes in mitochondrial function
[16]. This loss of oxidative capacity correlated with a
substantial decrease in the transcript levels of Pgc1α,
consistent with the direct regulation of Pgc1α expression
by mTOR [38], and could be restored by transgenic ex-
pression of PGC1α [22]. Contrary to the expectations
and the effect of mTORC1 activation in embryonic fi-
broblasts [38], all examined muscles of TSCmKO mice
showed a decreased expression of Pgc1α but increased
levels of Pgc1β. Thus, the increase in the oxidative cap-
acity in TSCmKO mice may be mediated by PGC1β. In-
deed, PGC1β has also been shown to be sufficient to
increase oxidative capacity in skeletal muscle despite the
concomitant reduction in PGC1α expression [60]. More-
over, depletion of both PGC1α and PGC1β results in
much more severe loss of oxidative capacity than deple-
tion of either protein alone [61]. The reason for the unex-
pected down-regulation of Pgc1α transcripts in TSCmKO
mice might be the counter-regulation of PGC1α and
PGC1β. We show here that overexpression of PGC1β in
C2C12 myotubes results in a strong suppression of the en-
dogenous Pgc1α expression and, conversely, Pgc1β knock-
down leads to increased expression of Pgc1α transcripts.
These data indicate that the total amount of both PGC1
co-activators is tightly controlled in skeletal muscle.
Conclusions
Our study provides new functional insights into the mo-
lecular mechanism of muscle atrophy and hypertrophy.
The data demonstrate that mTORC1 modulation down-
stream of PKB/Akt is subject to biological robustness. A
fine-tuned feedback loop controlled by the anabolic
mTORC1 pathway mediates crosstalk to E3 ubiquitin
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compensates for imbalance. However, this feedback sys-
tem fails to fully re-establish muscle homeostasis, lead-
ing to prevalence of either an anabolic or a catabolic net
response. Our observations emphasize that muscle growth
requires both activated PKB/Akt and mTORC1 in parallel,
and they provide a new rationale for the development of
pharmacologic agents that target this system.
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